Your browser doesn't support javascript.
loading
Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.
Casale, T B; Chipps, B E; Rosén, K; Trzaskoma, B; Haselkorn, T; Omachi, T A; Greenberg, S; Hanania, N A.
Affiliation
  • Casale TB; Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA.
  • Chipps BE; Capital Allergy & Respiratory Disease Center, Sacramento, CA, USA.
  • Rosén K; Genentech, Inc., South San Francisco, CA, USA.
  • Trzaskoma B; Genentech, Inc., South San Francisco, CA, USA.
  • Haselkorn T; EpiMetrix, Inc., Los Altos, CA, USA.
  • Omachi TA; Genentech, Inc., South San Francisco, CA, USA.
  • Greenberg S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Hanania NA; Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Allergy ; 73(2): 490-497, 2018 02.
Article in En | MEDLINE | ID: mdl-28859263
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Asthma / Anti-Asthmatic Agents / Omalizumab Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male Language: En Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Asthma / Anti-Asthmatic Agents / Omalizumab Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male Language: En Year: 2018 Type: Article